Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Tesla, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Tesla, Inc. trades at $403.88 (market cap $1.53T). The key difference: Tesla, Inc. is far larger — about 38.4× Alnylam Pharmaceuticals, Inc.'s market cap, and Tesla, Inc. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | TSLA | |
|---|---|---|
Market Cap | $39.89B | $1.53T |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $489.88 |
52-Week Low | $278.09 | $302.63 |
Enterprise Value | $38.15B | $1.50T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Tesla (TSLA) trades at $407.74, up 0.29% with neutral technical indicators and a bullish moving average signal. The company reported Q1 2026 EPS of $0.41, beating expectations, but revenue declined to $94.83B in 2025 with net income margin at 3.95%. Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV model, while analyst consensus remains mixed with a $436.41 price target.
Tesla's outlook balances innovation in autonomy and energy against slowing auto growth and high valuations. Investment opportunities lie in AI and robotics expansion, but risks include intense EV competition, margin pressure, and execution challenges. Wall Street sentiment is cautious despite long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
